Bookmark and Share
BioAssay: AID 602337

Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds

Name: Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds. ..more
_
   
 Tested Compounds
 Tested Compounds
All(6)
 
 
Inactive(6)
 
 
 Tested Substances
 Tested Substances
All(6)
 
 
Inactive(6)
 
 
 Related BioAssays
 Related BioAssays
AID: 602337
Data Source: The Scripps Research Institute Molecular Screening Center (NEURO2ACYTOX_INH_ABSORB_5XCC50)
BioAssay Type: Panel, Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network, Assay Provider
BioAssay Version:
Deposit Date: 2012-03-09
Hold-until Date: 2012-10-12
Modify Date: 2012-10-12

Data Table ( Complete ):           View All Data
Tested Compounds:
Related Experiments
Show more
AIDNameTypeProbeComment
504411Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)Screening depositor-specified cross reference: Primary screen (DAGLB inhibitors in singlicate)
504420Summary of the probe development efforts to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)Summary3 depositor-specified cross reference: Summary (DAGLB inhibitors)
504445Fluorescence-based biochemical high throughput confirmation assay for inhibitors of human diacylglycerol lipase, beta (DAGLB)Screening depositor-specified cross reference: ABPP screen (DABGLb inhibitors in triplicate)
602403Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of recombinant antitarget DAGLa in vitroOther depositor-specified cross reference
602415Assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LC/MS-based biochemical inhibition of overexpressed DAGLb substrate turnover in vitroOther depositor-specified cross reference
624039Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based dose-response biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of antitarget ABHD6 in vitro, set 2Confirmatory depositor-specified cross reference
624041Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of mouse liver ABHD6 in vivoOther depositor-specified cross reference
624077Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of mouse liver ABHD6 in vivo upon oral compound administrationOther depositor-specified cross reference
624468Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based biochemical dose response assayConfirmatory depositor-specified cross reference
624472Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of DAGLb by enantiomers of KT116Other depositor-specified cross reference
602299Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of overexpressed DAGLb in vitro set 2Other same project related to Summary assay
602300Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of overexpressed DAGLb in vitro set 3Other same project related to Summary assay
602301Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of recombinant anti-target ABHD11 in vitro set 1Other same project related to Summary assay
602302Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of overexpressed DAGLb in vitro set 1Other same project related to Summary assay
602303Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of overexpressed DAGLb in vitro; triazole urea libraryOther same project related to Summary assay
602311Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of serine hydrolases in mouse brain membrane in vitro set 1Other same project related to Summary assay
602312Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of recombinant anti-target ABHD11 in vitro set 2Other same project related to Summary assay
602319Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of antitarget ABHD6 in vitroOther same project related to Summary assay
602320Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based dose-response biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of DAGLb in vitroConfirmatory same project related to Summary assay
602321Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of serine hydrolases in mouse brain membrane in vitro set 3Other same project related to Summary assay
602322Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based dose-response biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of antitarget ABHD6 in vitroConfirmatory same project related to Summary assay
602323Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of serine hydrolases in mouse brain membrane in vitro set 2Other same project related to Summary assay
602335Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based dose-response biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of anti-target ABHD6 in situConfirmatory same project related to Summary assay
602339Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysisOther same project related to Summary assay
602341Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis for ABHD6Other same project related to Summary assay
602343Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of mouse brain ABHD6 in vivo, set 2Other same project related to Summary assay
602345Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of mouse macrophage DAGLb in vivoOther same project related to Summary assay
602347Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of mouse brain ABHD6 in vivoOther same project related to Summary assay
602349Late stage assay provider results from the probe development effort to identify inhibitors of DAGLb: fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) assay to distinguish systemic and peripheral inhibitorsOther same project related to Summary assay
602351Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based animal-based Activity-Based Protein Profiling (ABPP) MudPIT selectivity analysis for ABHD6Other same project related to Summary assay
602353Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based animal-based Activity-Based Protein Profiling (ABPP) MudPIT selectivity analysisOther same project related to Summary assay
602354Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical dose-response gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of DAGLb in situConfirmatory same project related to Summary assay
602355Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of serine hydrolases in vitroOther same project related to Summary assay
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Benjamin Cravatt, The Scripps Research Institute (TSRI)
Network: Molecular Library Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R01 DA025285
Grant Proposal PI: Benjamin Cravatt, The Scripps Research Institute (TSRI)
External Assay ID: NEURO2ACYTOX_INH_ABSORB_5XCC50

Name: Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds.

Description:

Endocannabinoids (ECs) represent a unique group of lipids that function as chemical messengers in the nervous system. To date, the two principle ECs identified in mammals are N-arachidonoyl-ethanolamine (anandamide) and 2-arachidonoyl-glycerol (2-AG). They have been implicated in various physiological and pathological functions including appetite, pain, sensation, memory, and addiction (1). Unlike traditional neurotransmitters, which are stored in vesicles, ECs are synthesized and released on demand, and then rapidly degraded to terminate signaling. Thus, the metabolic pathways that govern EC turnover are critical in determining the magnitude and duration of neuronal signaling events (2). Endocannabinoid biosynthesis, in contrast to degradation, is poorly understood. Recently, two serine hydrolases, DAGL-a and -B, were cloned and found to selectively cleave sn-1 acyl chains from diacylglycerols (DAG) to generate 2-AG in vitro (3). Their function in the nervous system was validated in vivo by the generation of DAGL-a and -B knock-out mice (4, 5). However, it is still unclear to what extent DAGL-a/B catalytic activity contributes to 2-AG-mediated signaling. The development of potent and selective inhibitors would offer a means to perturb DAGL-a/B activity in a selective, reversible, and temporally-controlled manner. Given the non-selective nature of current DAGL-a/B inhibitors (6), specific chemical probes would serve as invaluable tools to delineate DAGL-a/B function in 2-AG signaling networks of the brain.

References:

1. Di Marzo, V. (2008) Targeting the endocannabinoid system: to enhance or reduce?, Nat Rev Drug Discov 7, 438-455.
2. Ahn, K., McKinney, M. K., and Cravatt, B. F. (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system, Chem Rev 108, 1687-1707.
3. Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E. J., Gangadharan, U., Hobbs, C., Di Marzo, V., and Doherty, P. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain, J Cell Biol 163, 463-468.
4. Gao, Y., Vasilyev, D. V., Goncalves, M. B., Howell, F. V., Hobbs, C., Reisenberg, M., Shen, R., Zhang, M. Y., Strassle, B. W., Lu, P., Mark, L., Piesla, M. J., Deng, K., Kouranova, E. V., Ring, R. H., Whiteside, G. T., Bates, B., Walsh, F. S., Williams, G., Pangalos, M. N., Samad, T. A., and Doherty, P. (2010) Loss of Retrograde Endocannabinoid Signaling and Reduced Adult Neurogenesis in Diacylglycerol Lipase Knock-out Mice, J Neurosci 30, 2017-2024.
5. Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., Kita, Y., Hashimoto, K., Shimizu, T., Watanabe, M., Sakimura, K., and Kano, M. (2010) The Endocannabinoid 2-Arachidonoylglycerol Produced by Diacylglycerol Lipase +/- Mediates Retrograde Suppression of Synaptic Transmission, Neuron 65, 320-327.
6. Hoover, H. S., Blankman, J. L., Niessen, S., and Cravatt, B. F. (2008) Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling, Bioorganic & Medicinal Chemistry Letters 18, 5838-5841.

Keywords:

late stage, late stage AID, assay provider, powders, counterscreen, diacylglycerol lipase, diacylglycerol lipase-beta, DAGL, DAGL-beta, DAGLB, hydrolase, serine hydrolase, appetite, pain, sensation, memory, addiction, abhydrolase domain containing protein 6, ABHD6, cytotoxicity, Neuro-2A, CC50, dose response, Scripps, Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN
Panel Information
Assays
PID§NameSubstancePanel TargetsDescription
ActiveInactive
1Serum-free6
2Serum6

§ Panel component ID.
Protocol
Assay Overview:
The purpose of this assay is to determine cytotoxicity of powder samples of synthetic inhibitor compounds belonging to the triazole urea scaffold. In this assay, Neuro-2A murine neuroblastoma cells in either serum-free medium or medium containing fetal calf serum (FCS) are incubated with test compounds, followed by determination of cell viability. The assay utilizes the WST-1 substrate which is converted into colorimetric formazan dye by the metabolic activity of viable cells. The amount of formed formazan directly correlates to the number of metabolically active cells in the culture. As designed, compounds that reduce cell viability will result in decreased absorbance of the dye.
Protocol Summary:
This assay was started by dispensing Neuro-2A murine neuroblastoma cells in DMEM medium supplemented with 10% FCS (100 uL, 15,000 cells/well) into a 96-well plate. Cells were incubated for 24 hours at 37 C in a humidified incubator, medium was removed, and 100 uL of fresh, serum-free medium or medium supplemented with 10% FCS was added. Compound (10 uL of 11x stocks in medium containing 10% DMSO) or an equal volume medium containing 10% DMSO only was added to each well. Cells were incubated for 48 hours at 37 C in a humidified incubator and cell viability was determined by the WST-1 assay (Roche) according to manufacturer instructions. CC50 values were determined from dose-response curves from six replicates at each inhibitor concentration (100, 50, 10, 1, 0.1, and 0.01 uM).
The % cell viability for each well was calculated as follows:
%_Cell_Viability = ( ABS_Test_Compound - Median_ABS_Low_Control ) / ( Median_ABS_High_Control - Median_ABS_Low_Control ) * 100
Where:
Test_Compound is defined as wells containing cells in the presence of test compound.
High_Control is defined as wells containing cells treated with media only (no compound).
Low_Control is defined as wells containing no cells (media only).
The CC50 value for each test compound was determined by plotting percent surviving cells against the log of the compound concentration. A three parameter equation describing a sigmoidal dose-response curve was then fitted using GraphPad Prism (GraphPad Software Inc), and the software-generated CC50 values are reported. In the event that the highest test concentration did not result in at least 50% cell death, the CC50 value is reported as being greater than the highest test concentration.
PubChem Activity Outcome and Score:
The following applies to each panel in this assay:
Compounds with CC50 values less than or equal to 1 uM were considered active (cytotoxic). Compounds with CC50 values greater than 1 uM were considered inactive (non-cytotoxic).
Any compound with a percent activity value < 50% at all test concentrations was assigned an activity score of zero. Any compound with a percent activity value >= 50% at any test concentration was assigned an activity score greater than zero.
Activity score was then ranked by the potency of the compounds with fitted curves, with the most potent compounds assigned the highest activity scores.
Serum-free Score: The PubChem Activity Score range for inactive compounds is 100-0. There are no active compounds
Serum Score: The PubChem Activity Score range for inactive compounds is 100-1. There are no active compounds.
Overall Outcome and Score:
Compounds active in either assay were considered active (cytotoxic). Compounds inactive in both assays were considered inactive (non-cytotoxic).
The PubChem Activity Score is assigned a value of 100 for active compounds, and 0 for inactive compounds.
The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
List of Reagents:
DMEM Medium (CellGro 10-017-CV)
FCS (Omega Scientific, FB-01)
WST-1 reagent (Roche)
96-well plates (Corning)
Comment
This assay was performed by the assay provider with powder samples of synthetic compounds.
Categorized Comment - additional comments and annotations
From BioAssay Depositor:
BAO: assay format: biochemical format: protein format: single protein format
BAO: bioassay specification: assay biosafety level: bsl1
BAO: bioassay specification: assay measurement type: endpoint assay
BAO: bioassay specification: assay readout content: assay readout method: regular screening
BAO: bioassay specification: assay readout content: content readout type: single readout
BAO: bioassay specification: assay stage: secondary: counter screening
BAO: detection technology: fluorescence: fluorescence intensity
BAO: meta target detail: binding reporter specification: interaction: protein-small molecule
BAO: meta target: biological process target: regulation of molecular function
BAO: meta target: molecular target: protein target: enzyme: generic hydrolase
BAO: version: 1.4b1090
From PubChem:
Assay Format: Cell-based
Assay Type: Toxicity
Assay Cell Type: Neuro-2A
Result Definitions
Show more
TIDNameDescriptionPID§Panel TargetsHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1Outcome [Serum-free]One of Active, Inactive, or Not Tested1Outcome
2Score [Serum-free]The BioAssay activity ranking score. (See PubChem Activity Outcome and Score section in Protocol for details.)1Integer
3Qualifier [Serum-free]Qualifier identifies if the resultant CC50 was determined manually to be greater than its listed CC50.1String
4CC50 [Serum-free]*The value for the concentration at which 50% of surviving cells are observed in serum-free medium; CC50 shown in micromolar.1FloatμM
5Cell Viability at 100 uM [1, Serum-free] (100μM**)Value of % cell viability at 100 uM compound concentration in serum-free medium; replicate [1]1Float%
6Cell Viability at 100 uM [2, Serum-free] (100μM**)Value of % cell viability at 100 uM compound concentration in serum-free medium; replicate [2]1Float%
7Cell Viability at 100 uM [3, Serum-free] (100μM**)Value of % cell viability at 100 uM compound concentration in serum-free medium; replicate [3]1Float%
8Cell Viability at 100 uM [4, Serum-free] (100μM**)Value of % cell viability at 100 uM compound concentration in serum-free medium; replicate [4]1Float%
9Cell Viability at 100 uM [5, Serum-free] (100μM**)Value of % cell viability at 100 uM compound concentration in serum-free medium; replicate [5]1Float%
10Cell Viability at 50 uM [1, Serum-free] (50μM**)Value of % cell viability at 50 uM compound concentration in serum-free medium; replicate [1]1Float%
11Cell Viability at 50 uM [2, Serum-free] (50μM**)Value of % cell viability at 50 uM compound concentration in serum-free medium; replicate [2]1Float%
12Cell Viability at 50 uM [3, Serum-free] (50μM**)Value of % cell viability at 50 uM compound concentration in serum-free medium; replicate [3]1Float%
13Cell Viability at 50 uM [4, Serum-free] (50μM**)Value of % cell viability at 50 uM compound concentration in serum-free medium; replicate [4]1Float%
14Cell Viability at 50 uM [5, Serum-free] (50μM**)Value of % cell viability at 50 uM compound concentration in serum-free medium; replicate [5]1Float%
15Cell Viability at 10 uM [1, Serum-free] (10μM**)Value of % cell viability at 10 uM compound concentration in serum-free medium; replicate [1]1Float%
16Cell Viability at 10 uM [2, Serum-free] (10μM**)Value of % cell viability at 10 uM compound concentration in serum-free medium; replicate [2]1Float%
17Cell Viability at 10 uM [3, Serum-free] (10μM**)Value of % cell viability at 10 uM compound concentration in serum-free medium; replicate [3]1Float%
18Cell Viability at 10 uM [4, Serum-free] (10μM**)Value of % cell viability at 10 uM compound concentration in serum-free medium; replicate [4]1Float%
19Cell Viability at 10 uM [5, Serum-free] (10μM**)Value of % cell viability at 10 uM compound concentration in serum-free medium; replicate [5]1Float%
20Cell Viability at 1 uM [1, Serum-free] (1μM**)Value of % cell viability at 1 uM compound concentration in serum-free medium; replicate [1]1Float%
21Cell Viability at 1 uM [2, Serum-free] (1μM**)Value of % cell viability at 1 uM compound concentration in serum-free medium; replicate [2]1Float%
22Cell Viability at 1 uM [3, Serum-free] (1μM**)Value of % cell viability at 1 uM compound concentration in serum-free medium; replicate [3]1Float%
23Cell Viability at 1 uM [4, Serum-free] (1μM**)Value of % cell viability at 1 uM compound concentration in serum-free medium; replicate [4]1Float%
24Cell Viability at 1 uM [5, Serum-free] (1μM**)Value of % cell viability at 1 uM compound concentration in serum-free medium; replicate [5]1Float%
25Cell Viability at 0.1 uM [1, Serum-free] (0.1μM**)Value of % cell viability at 0.1 uM compound concentration in serum-free medium; replicate [1]1Float%
26Cell Viability at 0.1 uM [2, Serum-free] (0.1μM**)Value of % cell viability at 0.1 uM compound concentration in serum-free medium; replicate [2]1Float%
27Cell Viability at 0.1 uM [3, Serum-free] (0.1μM**)Value of % cell viability at 0.1 uM compound concentration in serum-free medium; replicate [3]1Float%
28Cell Viability at 0.1 uM [4, Serum-free] (0.1μM**)Value of % cell viability at 0.1 uM compound concentration in serum-free medium; replicate [4]1Float%
29Cell Viability at 0.1 uM [5, Serum-free] (0.1μM**)Value of % cell viability at 0.1 uM compound concentration in serum-free medium; replicate [5]1Float%
30Cell Viability at 0.01 uM [1, Serum-free] (0.01μM**)Value of % cell viability at 0.01 uM compound concentration in serum-free medium; replicate [1]1Float%
31Cell Viability at 0.01 uM [2, Serum-free] (0.01μM**)Value of % cell viability at 0.01 uM compound concentration in serum-free medium; replicate [2]1Float%
32Cell Viability at 0.01 uM [3, Serum-free] (0.01μM**)Value of % cell viability at 0.01 uM compound concentration in serum-free medium; replicate [3]1Float%
33Cell Viability at 0.01 uM [4, Serum-free] (0.01μM**)Value of % cell viability at 0.01 uM compound concentration in serum-free medium; replicate [4]1Float%
34Cell Viability at 0.01 uM [5, Serum-free] (0.01μM**)Value of % cell viability at 0.01 uM compound concentration in serum-free medium; replicate [5]1Float%
35Outcome [Serum]One of Active, Inactive, or Not Tested2Outcome
36Score [Serum]The BioAssay activity ranking score. (See PubChem Activity Outcome and Score section in Protocol for details.)2Integer
37Qualifier [Serum]Qualifier identifies if the resultant CC50 was determined manually to be greater than its listed CC50.2String
38CC50 [Serum]*The value for the concentration at which 50% of surviving cells are observed in serum-containing medium; CC50 shown in micromolar.2FloatμM
39Cell Viability at 100 uM [1, Serum] (100μM**)Value of % cell viability at 100 uM compound concentration in serum-supplemented medium; replicate [1]2Float%
40Cell Viability at 100 uM [2, Serum] (100μM**)Value of % cell viability at 100 uM compound concentration in serum-supplemented medium; replicate [2]2Float%
41Cell Viability at 100 uM [3, Serum] (100μM**)Value of % cell viability at 100 uM compound concentration in serum-supplemented medium; replicate [3]2Float%
42Cell Viability at 100 uM [4, Serum] (100μM**)Value of % cell viability at 100 uM compound concentration in serum-supplemented medium; replicate [4]2Float%
43Cell Viability at 100 uM [5, Serum] (100μM**)Value of % cell viability at 100 uM compound concentration in serum-supplemented medium; replicate [5]2Float%
44Cell Viability at 50 uM [1, Serum] (50μM**)Value of % cell viability at 50 uM compound concentration in serum-supplemented medium; replicate [1]2Float%
45Cell Viability at 50 uM [2, Serum] (50μM**)Value of % cell viability at 50 uM compound concentration in serum-supplemented medium; replicate [2]2Float%
46Cell Viability at 50 uM [3, Serum] (50μM**)Value of % cell viability at 50 uM compound concentration in serum-supplemented medium; replicate [3]2Float%
47Cell Viability at 50 uM [4, Serum] (50μM**)Value of % cell viability at 50 uM compound concentration in serum-supplemented medium; replicate [4]2Float%
48Cell Viability at 50 uM [5, Serum] (50μM**)Value of % cell viability at 50 uM compound concentration in serum-supplemented medium; replicate [5]2Float%
49Cell Viability at 10 uM [1, Serum] (10μM**)Value of % cell viability at 10 uM compound concentration in serum-supplemented medium; replicate [1]2Float%
50Cell Viability at 10 uM [2, Serum] (10μM**)Value of % cell viability at 10 uM compound concentration in serum-supplemented medium; replicate [2]2Float%
51Cell Viability at 10 uM [3, Serum] (10μM**)Value of % cell viability at 10 uM compound concentration in serum-supplemented medium; replicate [3]2Float%
52Cell Viability at 10 uM [4, Serum] (10μM**)Value of % cell viability at 10 uM compound concentration in serum-supplemented medium; replicate [4]2Float%
53Cell Viability at 10 uM [5, Serum] (10μM**)Value of % cell viability at 10 uM compound concentration in serum-supplemented medium; replicate [5]2Float%
54Cell Viability at 1 uM [1, Serum] (1μM**)Value of % cell viability at 1 uM compound concentration in serum-supplemented medium; replicate [1]2Float%
55Cell Viability at 1 uM [2, Serum] (1μM**)Value of % cell viability at 1 uM compound concentration in serum-supplemented medium; replicate [2]2Float%
56Cell Viability at 1 uM [3, Serum] (1μM**)Value of % cell viability at 1 uM compound concentration in serum-supplemented medium; replicate [3]2Float%
57Cell Viability at 1 uM [4, Serum] (1μM**)Value of % cell viability at 1 uM compound concentration in serum-supplemented medium; replicate [4]2Float%
58Cell Viability at 1 uM [5, Serum] (1μM**)Value of % cell viability at 1 uM compound concentration in serum-supplemented medium; replicate [5]2Float%
59Cell Viability at 0.1 uM [1, Serum] (0.1μM**)Value of % cell viability at 0.1 uM compound concentration in serum-supplemented medium; replicate [1]2Float%
60Cell Viability at 0.1 uM [2, Serum] (0.1μM**)Value of % cell viability at 0.1 uM compound concentration in serum-supplemented medium; replicate [2]2Float%
61Cell Viability at 0.1 uM [3, Serum] (0.1μM**)Value of % cell viability at 0.1 uM compound concentration in serum-supplemented medium; replicate [3]2Float%
62Cell Viability at 0.1 uM [4, Serum] (0.1μM**)Value of % cell viability at 0.1 uM compound concentration in serum-supplemented medium; replicate [4]2Float%
63Cell Viability at 0.1 uM [5, Serum] (0.1μM**)Value of % cell viability at 0.1 uM compound concentration in serum-supplemented medium; replicate [5]2Float%
64Cell Viability at 0.01 uM [1, Serum] (0.01μM**)Value of % cell viability at 0.01 uM compound concentration in serum-supplemented medium; replicate [1]2Float%
65Cell Viability at 0.01 uM [2, Serum] (0.01μM**)Value of % cell viability at 0.01 uM compound concentration in serum-supplemented medium; replicate [2]2Float%
66Cell Viability at 0.01 uM [3, Serum] (0.01μM**)Value of % cell viability at 0.01 uM compound concentration in serum-supplemented medium; replicate [3]2Float%
67Cell Viability at 0.01 uM [4, Serum] (0.01μM**)Value of % cell viability at 0.01 uM compound concentration in serum-supplemented medium; replicate [4]2Float%
68Cell Viability at 0.01 uM [5, Serum] (0.01μM**)Value of % cell viability at 0.01 uM compound concentration in serum-supplemented medium; replicate [5]2Float%

* Activity Concentration. ** Test Concentration. § Panel component ID.
Additional Information
Grant Number: 1 R01 DA025285

PageFrom: